Provided by Tiger Trade Technology Pte. Ltd.

VistaGen Therapeutics

3.60
-0.8300-18.74%
Post-market: 3.59-0.0100-0.28%18:11 EST
Volume:1.54M
Turnover:6.03M
Market Cap:142.18M
PE:-1.88
High:4.42
Open:4.41
Low:3.54
Close:4.43
52wk High:5.14
52wk Low:1.90
Shares:39.50M
Float Shares:30.75M
Volume Ratio:1.71
T/O Rate:5.02%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.9154
EPS(LYR):-1.6652
ROE:-78.13%
ROA:-44.62%
PB:2.14
PE(LYR):-2.16

Loading ...

Vistagen Therapeutics Inc expected to post a loss of 48 cents a share - Earnings Preview

Reuters
·
Nov 03

BRIEF-Vistagen Appoints Paul Edick To Its Board Of Directors

Reuters
·
Oct 29

VistaGen Therapeutics Appoints Paul Edick to Board of Directors

Reuters
·
Oct 29

Vistagen Appoints Paul Edick to Its Board of Directors

THOMSON REUTERS
·
Oct 29

William Blair Reaffirms Their Buy Rating on VistaGen Therapeutics (VTGN)

TIPRANKS
·
Oct 29

VistaGen Therapeutics to Present New Clinical Data on PH80 Nasal Spray for Menopausal Hot Flashes at The Menopause Society 2025 Annual Meeting

Reuters
·
Oct 16

BRIEF-Vistagen Therapeutics CFO Cynthia L. Anderson Resigns - SEC Filing

Reuters
·
Sep 16

VistaGen Therapeutics CFO Resignation Announced

TIPRANKS
·
Sep 16

Vistagen Therapeutics Inc - CFO Cynthia L. Anderson Resigns Effective October 15, 2025 - SEC Filing

THOMSON REUTERS
·
Sep 16

VistaGen Therapeutics Inc. Held Annual Stockholders Meeting

Reuters
·
Sep 16

VistaGen Therapeutics Inc. to Present at TD Cowen 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit

Reuters
·
Sep 09

Vistagen Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary

Reuters
·
Aug 08

Biopharmaceutical firm VistaGen Q1 net loss widens

Reuters
·
Aug 08

VistaGen Therapeutics Inc. Reports Q1 Fiscal Year 2026 Results: Net Loss Widens to $15.1M, R&D Expenses Increase by 54%

Reuters
·
Aug 08

Vistagen Reports Fiscal Year 2026 First Quarter Financial Results and Corporate Update

THOMSON REUTERS
·
Aug 08

Vistagen Therapeutics Inc expected to post a loss of 47 cents a share - Earnings Preview

Reuters
·
Aug 06

VistaGen Therapeutics Inc. to Announce Fiscal Year 2026 First Quarter Results

Reuters
·
Jul 31

VistaGen Therapeutics Inc. Announces Date for 2025 Annual Meeting of Stockholders

Reuters
·
Jul 29

VistaGen Therapeutics Appoints Elissa Cote as Chief Corporate Development Officer to Drive Strategic Growth

Reuters
·
Jun 25

VistaGen Therapeutics Q4 EPS $(0.44) Beats $(0.50) Estimate, Sales $(15.00K)

Benzinga
·
Jun 18